Over de innovatie
• Meal logging focuses on the four daily nutrients that have to be specifically restricted in a CKD patient's diet - sodium, phosphorus, potassium, and protein;
• One-on-one nutrition and lifestyle coaching with a renal nurse, dietitian, or health coach depending on the patient’s specific health needs;
• Behavior change reinforcement through a development collaboration with the US Stanford University's Persuasive Tech Labs;
• A 12-week educational bootcamp based on the US/UK Diabetes Prevention Program and National Kidney Foundation guidelines;
• Predictive analytics in collaboration with Dutch data science company Orikami.
Version 2.0 (2018Q2):
• Adaptation into a 16-week educational bootcamp of the STERK (STimuleren van Eigen Regie en Kwaliteit van leven van mensen met chronische nierschade) content. This was developed by the Universitair Medisch Centrum Groningen in collaboration with 4 other Dutch hospitals, and sponsored by Nierstichting Nederlands;
• One-on-one lifestyle coaching will be done by STERK-certified Trainers;
• A translated version of the iOS application in Dutch.
RenalTracker's technology is based on cutting-edge platforms while giving major importance in privacy and security. The application is using Play Framework-Java and Scala on templating. It's using Angular, spring and JPA for front-end and a combination of memcache and PSQL database for the backend. The first mobile application version (iOS launching 2018Q1) is being developed using NativeScript which allows for cross-platform flexibility. For security and privacy, we had a quick scan done by Delloite and passed it with above average rating.
Other alternatives that patients use are mostly dialysis clinics that generate leads via online channel and don't have health coaches, like Davita. Aside from this, patients also use general dieting apps like MyFitnessPal.
While there are apps that are offering kidney disease focused dieting, they don't have health coaches or a behavior change-focused curriculum.
We are currently developing our B2B models for the Dutch market in 2018Q2.
From what we've learned, we created digital kidney guidebooks as our Minimum Viable Products (MVP) and sold them to kidney patients at prices ranging from $7 to $47.
To date, we sold more than 5,000 copies of these kidney guidebooks. After optimizing our marketing funnel, we were able to get 14% leads-to-sales conversion rate. We are now at the point where we have validated that patients are indeed willing to pay for the solution that we're offering.
So we developed RenalTracker and launched it on September 2016. To date, we have 429 paying users since launch with some very promising initial results from early adopters. This allowed us to validate that RenalTracker is in the right direction in helping patients.
Tier 1 will use a Perceived Self-Efficacy questionnaire to measure patient’s overall sense of well-being and ease of program compliance after the 16-week core curriculum. It also establishes baseline CKD-related laboratory test values per patient. Tier 2 documents CKD-related laboratory test values per patient at the end of the 24-week intervention.
Subjects will be recruited exclusively through hospital partners to have a more consistent control group using standard therapy. Primary activities include regular physician consultation visits and laboratory tests, the frequency of which will be determined when the hospital partner is selected.
Other product development partners: Stanford Persuasive Tech Labs (US) for behavior change and Orikami (Netherlands) for data science.
RenalTracker is also working with Vital Innovators (Netherlands) to conduct further market research and develop our B2B models based on a Social Return on Investment analysis.
Karen Naranjo, Co-Founder and VP for Business Development, heads the global markets head of a US-based dermatology company selling clinically-validated dermatitis products. She will lead the efforts on clinical validation, product development (Dutch market adaptation), and B2B development.
Karl Quint, RenalTracker's Chief Medical Officer, is a healthcare advisor, medical doctor & PhD with clinical experience in internal medicine and pathology. He has broad experience in basic, clinical and translational research. Karl led the Translational Research Lab at the Institute for Surgical Research (University of Marburg, Germany) and conducted international research projects in basic and clinical research.
David Ngo, is from Stanford University's persuasive tech labs. He's a colleague and co-author of Dr BJ Fogg, one of the world's foremost experts in behavior change. Nic Chapa, also from Stanford Persuasive Tech Labs, is our product manager for the iOS launch.
Paul Labis, is a 9-year full-stack software engineer consulting for US-based companies in the past 3 years.
The bigger picture in our roadmap is in reimbursements where insurance companies will pay for the services that patients get from RenalTracker. This will come after we have proven that the curriculum, does, in fact, delay the progression of patients to dialysis compared to the standard course of patient treatment. However, this will only come after at least 1.5 to 2 years of running the clinical validation. In the meantime, we are building a case for the Netherlands and Belgium as B2B.
For the next 12-18 months, we are focused only on targeting four major English-speaking countries in the US, UK, Canada and Australia for B2C.
In parallel, we will also start to focus on Content Marketing where we will be writing high-value articles on our blog and build an audience around it via social media.
Our marketing message will focus on our unique position as a low-cost, high value partner in managing patient's chronic kidney disease.
The company is already in discussions with institutions in the Netherlands and Belgium (through NephroFlow's network - CHU Brugmann, Jessa Hospital, AZ Sint-Lucas) for clinical validation of both platforms.
Launch iOS Native App
Evidence-based, EU-adapted curriculum with UMCG
Integrate predictive analytics
Translate to Dutch
Acquisition: Experiments, experiments, experiments
User retention, Stickiness & Engagement
B2B Roadmap based on Social Return on Investment analysis
Run In-App > Partner Pilot > Full Clinical Validation (MEDDEV and MDR 2017/745)